Guiding a Pioneering Technology Through FDA Strategy and Clinical Alignment
A medical device innovator developing a novel, ultrasound-based technology to evaluate organ tissue characteristics approached AlvaMed with a critical challenge: defining a viable FDA regulatory pathway for a device with no clear predicate and a complex clinical strategy with trials already underway in advance of FDA interaction.
AlvaMed partnered closely with the client as a strategic regulatory advisor, with Eric Bannon and Keira Jessop leading efforts to align regulatory positioning, clinical evidence, and overall testing strategy.
The Challenge: Aligning Clinical Strategy with Regulatory Uncertainty
The client had already initiated a clinical study targeting a specific cardiac disease state before receiving FDA feedback. While this accelerated development timelines, it introduced regulatory risk as the first FDA Pre-Submission was completed:
- The initial assumption was a 510(k) pathway
- FDA feedback indicated the device was more appropriate for a De Novo classification due to its specific disease specific diagnostic intended use
- Clinical data was being generated for a narrow disease indication, limiting its applicability to a broader regulatory strategy
Additionally, questions arose around:
- How to generalize clinical data collected from a specific pathology to a generalized intended use
- Whether existing bench testing was sufficient
- What additional evidence would be required to support a future submission
AlvaMed’s Approach: Strategic Realignment and FDA Engagement
AlvaMed worked closely with the client to optimize both regulatory and clinical strategies while maintaining development momentum.
1. Regulatory Pathway Repositioning
- Led multiple FDA Q-Sub (Pre-Submission) interactions to achieve the company’s regulatory objectives
- Successfully reframed the device’s intended use from a disease-specific claim to a broader clinical application
- Positioned the device back toward a potential 510(k) pathway, reducing regulatory burden
2. Clinical Strategy Optimization
- Developed a justification for leveraging existing clinical data despite its disease-specific design
- Demonstrated to FDA that the study design enabled representation of a range of organ tissue characteristics, not just a single pathology
- Helped align clinical endpoints with regulatory expectations and requirements
3. Evidence Strategy & Testing Alignment
- Addressed FDA concerns regarding reliance on bench testing through the addition of animal evaluation
- Negotiated a balanced approach incorporating:
- Clinical data
- Bench testing
- Animal Evaluation to further support device performance
This multi-pronged strategy ensured scientific rigor and a pathway to demonstrating substantial equivalence.
Key Challenge Overcome
A key hurdle was convincing FDA that clinical data collected from a disease-specific population could support a broader, non-disease-specific intended use.
AlvaMed successfully demonstrated that:
- The study’s design inherently captured a spectrum of organ tissue conditions
- The targeted disease states were a means to access variability in tissue properties, not the intended clinical diagnostic claim
This distinction was critical in aligning the regulatory pathway with a more efficient submission strategy.
Outcome
- Regulatory pathway clarified and optimized
- Intended use refined to align with FDA requirements while preserving the client’s marketing position
- Clinical data strategy preserved leveraging planned data with no new clinical requirements
- Testing strategy expanded to address FDA concerns
- Clear roadmap established for future FDA submission
Impact
By integrating regulatory expertise early and engaging proactively with FDA, AlvaMed enabled the client to:
- Avoid costly additional clinical studies
- Reduce regulatory uncertainty
- Maintain development timelines
- Position the device for a more efficient market entry pathway
Conclusion
This engagement highlights the importance of aligning clinical development and regulatory strategy early – especially for novel technologies without clear predicate devices.
AlvaMed’s ability to navigate ambiguity, engage effectively with FDA, and adapt strategy in real time allowed the client to move forward with confidence and clarity.
